Managing Agitation Associated with Schizophrenia and Bipolar Disorder in the Emergency Setting
- PMID: 26973742
- PMCID: PMC4786236
- DOI: 10.5811/westjem.2015.12.28763
Managing Agitation Associated with Schizophrenia and Bipolar Disorder in the Emergency Setting
Abstract
Introduction: Patient agitation represents a significant challenge in the emergency department (ED), a setting in which medical staff are working under pressure dealing with a diverse range of medical emergencies. The potential for escalation into aggressive behavior, putting patients, staff, and others at risk, makes it imperative to address agitated behavior rapidly and efficiently. Time constraints and limited access to specialist psychiatric support have in the past led to the strategy of "restrain and sedate," which was believed to represent the optimal approach; however, it is increasingly recognized that more patient-centered approaches result in improved outcomes. The objective of this review is to raise awareness of best practices for the management of agitation in the ED and to consider the role of new pharmacologic interventions in this setting.
Discussion: The Best practices in Evaluation and Treatment of Agitation (BETA) guidelines address the complete management of agitation, including triage, diagnosis, interpersonal calming skills, and medicine choices. Since their publication in 2012, there have been further developments in pharmacologic approaches for dealing with agitation, including both new agents and new modes of delivery, which increase the options available for both patients and physicians. Newer modes of delivery that could be useful in rapidly managing agitation include inhaled, buccal/sublingual and intranasal formulations. To date, the only formulation administered via a non-intramuscular route with a specific indication for agitation associated with bipolar or schizophrenia is inhaled loxapine. Non-invasive formulations, although requiring cooperation from patients, have the potential to improve overall patient experience, thereby improving future cooperation between patients and healthcare providers.
Conclusion: Management of agitation in the ED should encompass a patient-centered approach, incorporating non-pharmacologic approaches if feasible. Where pharmacologic intervention is necessary, a cooperative approach using non-invasive medications should be employed where possible.
Similar articles
-
Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder.Int J Clin Pract. 2011 Mar;65(3):330-40. doi: 10.1111/j.1742-1241.2010.02615.x. Epub 2010 Dec 29. Int J Clin Pract. 2011. PMID: 21199198 Review.
-
Inhaled loxapine for the urgent treatment of acute agitation associated with schizophrenia or bipolar disorder.Curr Med Res Opin. 2016 Jul;32(7):1253-60. doi: 10.1185/03007995.2016.1170004. Epub 2016 Jun 1. Curr Med Res Opin. 2016. PMID: 27121764 Review.
-
Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder.BMC Psychiatry. 2017 Apr 4;17(1):126. doi: 10.1186/s12888-017-1291-5. BMC Psychiatry. 2017. PMID: 28376877 Free PMC article. Clinical Trial.
-
Inhaled Loxapine for the Management of Acute Agitation in Bipolar Disorder and Schizophrenia: Expert Review and Commentary in an Era of Change.Drugs R D. 2019 Mar;19(1):15-25. doi: 10.1007/s40268-019-0262-3. Drugs R D. 2019. PMID: 30721526 Free PMC article. Review.
-
Safety and efficacy of self-administered inhaled loxapine (ADASUVE) in agitated patients outside the hospital setting: protocol for a phase IV, single-arm, open-label trial.BMJ Open. 2018 Oct 2;8(10):e020242. doi: 10.1136/bmjopen-2017-020242. BMJ Open. 2018. PMID: 30282677 Free PMC article.
Cited by
-
Associations of C-Reactive Protein, Free Triiodothyronine, Thyroid Stimulating Hormone and Creatinine Levels with Agitation in Patients with Schizophrenia: A Comparative Cross-Sectional Study.Neuropsychiatr Dis Treat. 2021 Aug 10;17:2575-2585. doi: 10.2147/NDT.S322005. eCollection 2021. Neuropsychiatr Dis Treat. 2021. PMID: 34408419 Free PMC article.
-
Transdermal Delivery of Antipsychotics: Rationale and Current Status.CNS Drugs. 2019 Sep;33(9):849-865. doi: 10.1007/s40263-019-00659-7. CNS Drugs. 2019. PMID: 31493244 Review.
-
Inhaled Loxapine for the Treatment of Psychiatric Agitation in the Prehospital Setting: A Case Series.Clin Pract Cases Emerg Med. 2017 Oct 6;1(4):345-348. doi: 10.5811/cpcem.2017.5.33840. eCollection 2017 Nov. Clin Pract Cases Emerg Med. 2017. PMID: 29849385 Free PMC article.
-
Sublingual Dexmedetomidine for the Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder.Clin Psychopharmacol Neurosci. 2023 May 30;21(2):215-221. doi: 10.9758/cpn.2023.21.2.215. Clin Psychopharmacol Neurosci. 2023. PMID: 37119214 Free PMC article. Review.
-
"Pharmacological management of acute agitation in psychiatric patients: an umbrella review".BMC Psychiatry. 2025 Mar 25;25(1):273. doi: 10.1186/s12888-024-06426-3. BMC Psychiatry. 2025. PMID: 40133850 Free PMC article.
References
-
- Weiss AP, Chang G, Rauch SL, et al. Patient- and practice-related determinants of emergency department length of stay for patients with psychiatric illness. Ann Emerg Med. 2012;60(2):162–71. - PubMed
-
- Marder SR. A review of agitation in mental illness: treatment guidelines and current therapies. J Clin Psychiatry. 2006;67(Suppl 10):13–21. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous